Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.170
-0.060 (-2.69%)
Mar 18, 2026, 2:49 PM EDT - Market open

BDTX Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
22.37-69.68-82.44-91.17-125.6
Depreciation & Amortization
-0.95-3.44-0.741.042.39
Stock-Based Compensation
6.6310.639.612.214.04
Other Adjustments
10.32.883.172.752
Changes in Accounts Payable
-3.431.680.6-2.231.57
Changes in Accrued Expenses
-1.41-0.763.94-5.868.71
Changes in Other Operating Activities
-3.89-3.62-0.85-1.81-3.26
Operating Cash Flow
29.61-62.3-66.72-85.08-100.15
Capital Expenditures
---0.03-0.19-2.71
Sale of Property, Plant & Equipment
0.030.090.10.01-
Purchases of Investments
-164.03-122.88-61.89-60.14-49.51
Proceeds from Sale of Investments
119.09139.7578.17113.69182.83
Investing Cash Flow
-44.9116.9716.3553.37130.61
Issuance of Common Stock
-0.1525.5571.930.180.73
Net Common Stock Issued (Repurchased)
-0.1525.5571.930.180.73
Financing Cash Flow
-0.1525.5571.930.180.73
Net Cash Flow
-15.44-19.7921.56-31.5431.19
Free Cash Flow
29.61-62.3-66.75-85.27-102.86
FCF Margin
42.31%----
Free Cash Flow Per Share
0.51-1.13-1.52-2.35-2.84
Levered Free Cash Flow
12.69-75.81-79.53-100.22-118.9
Unlevered Free Cash Flow
2.84-84.91-83.54-101.88-120.17
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q